Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Thromboaspiration for acute upper limb ischemia in a patient with COVID-19 (case report)].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery·2026
Same author

[Molecular study of mechanisms of action of cilostazol on certain families of phosphodiesterases].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery·2025
Same author

Comparison of management options for spontaneous bleeding into soft tissues in patients with COVID-19.

Scientific reports·2025
Same author

[Drug monitoring of the antibacterial drug Vancomycin in patients with purulent-inflammatory diseases of the maxillofacial region].

Stomatologiia·2023
Same author

IgG Stimulates the Formation of Neutrophil Extracellular Traps and Modifies Their Structure.

Bulletin of experimental biology and medicine·2023
Same author

Increased reliability of CT-imaging signs of bleeding into soft tissue in patients with COVID-19 for planning transarterial embolization.

Abdominal radiology (New York)·2023

Related Experiment Videos

[Lethality after gastroduodenal ulcer bleeding].

V A Stupin, M V Baglaenko, V I Kan

    Khirurgiia
    |May 30, 2013
    PubMed
    Summary

    Gastroduodenal ulcer bleeding is often fatal, with most deaths due to comorbidities like organ failure and cardiovascular disease, not the bleeding itself. The Rockall score effectively predicts mortality risk in these patients.

    Related Experiment Videos

    Area of Science:

    • Gastroenterology
    • Internal Medicine
    • Critical Care Medicine

    Context:

    • Retrospective analysis of 895 patients with gastroduodenal ulcer bleeding (2006-2010).
    • Overall mortality was 24.6%, with 5% directly attributed to ulcer bleeding.
    • Identified comorbidities significantly impacting mortality.

    Purpose:

    • To analyze mortality causes in gastroduodenal ulcer bleeding patients.
    • To evaluate the prognostic value of the Rockall score.
    • To understand the role of comorbidities in patient outcomes.

    Summary:

    • Hemorrhagic shock and recurrent bleeding were primary causes of death directly from bleeding.
    • Comorbidities, including multiple organ failure (36%), cardiovascular diseases (24.4%), and oncology (15.9%), accounted for approximately 80% of non-bleeding-related deaths.
    • The Rockall score demonstrated significant prognostic value (mean scores: 4.3±2.12 survived vs. 7.16±2.35 died, p=0.001).

    Impact:

    • Highlights the critical role of managing comorbidities in improving survival rates for gastroduodenal ulcer bleeding.
    • Emphasizes the need for accurate death cause attribution, avoiding misinterpretation due to underlying conditions.
    • Validates the Rockall score as a crucial tool for risk stratification and clinical decision-making in managing gastrointestinal bleeding.